Basking Biosciences

Basking Biosciences is pioneering a new approach to treating acute thrombosis by targeting von Willebrand Factor (vWF) with a short-acting, reversible RNA aptamer therapy. The company's platform combines BB-031, a vWF inhibitor, with BB-025, a specific reversal agent, designed to enable precise control during critical interventions like stroke. Led by an experienced team with deep expertise in thrombosis and drug development, Basking is advancing its lead program through clinical trials to address a significant unmet need in vascular emergencies. The company is privately held and pre-revenue, focusing on demonstrating the safety and efficacy of its novel therapeutic paradigm.

RNA aptamer platform targeting von Willebrand Factor (vWF) with a built-in, direct-acting reversal agent for precise control of therapeutic activity.

Basking competes in the acute anticoagulant/thrombolytic space, facing off against the standard-of-care tPA, newer thrombolytics, and anticoagulants like heparin and direct oral anticoagulants (DOACs), though DOACs are not for acute use. Its key differentiator is rapid reversibility, a feature lacking in most competitors. It also competes with other vWF-targeting agents in development and with mechanical thrombectomy devices. Its niche is the intersection of potency and controllability.